Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Evinova will operate as a separate health-tech business within AstraZeneca
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Subscribe To Our Newsletter & Stay Updated
